


# Claims

1. An enhancer for increasing gene transfer efficiency in a gene transfer mediated by an adeno-associated virus vector, the enhancer containing a histone deacetylase inhibitor as an active ingredient.
2. The enhancer as described in claim 1, wherein the histone deacetylase inhibitor is a compound represented by formula (I):




or a salt of the compound.

3. The enhancer as described in claim 1 or 2, wherein the gene transfer is performed to tumor cells.
4. The enhancer as described in any one of claims 1 to 3, which is a pharmaceutical drug.
5. The enhancer as described in claim 4, wherein the pharmaceutical drug is for gene therapy.
6. The enhancer as described in claim 5, wherein the gene therapy is performed against cancer.

7. A method for increasing gene transfer efficiency in a gene transfer mediated by an adeno-associated virus vector, the method comprising administering an effective dose of a histone deacetylase inhibitor to a subject in need of an increase in the gene transfer efficiency in a gene transfer mediated by an adeno-associated virus vector.

8. The method as described in claim 7, wherein the histone deacetylase inhibitor is a compound represented by formula (I):



or a salt of the compound.

9. The method as described in claim 7 or 8, wherein the gene transfer is performed to tumor cells.


10. The method as described in any one of claims 7 to 9, which is performed for gene therapy.

11. The method as described in claim 10, wherein the gene therapy is performed against cancer.

12. Use of a histone deacetylase inhibitor for producing an

enhancer for increasing gene transfer efficiency in a gene transfer mediated by an adeno-associated virus vector.

13. The use as described in claim 12, wherein the histone deacetylase inhibitor is a compound represented by formula (I):



or a salt of the compound.

14. The use as described in claim 12 or 13, wherein the gene transfer is performed to tumor cells.

15. The use as described in any one of claims 12 through 14, wherein the enhancer for increasing gene transfer efficiency in a gene transfer mediated by an adeno-associated virus vector is a pharmaceutical drug.

16. The use as described in claim 15, wherein the pharmaceutical drug is for gene therapy.

17. The use as described in claim 16, wherein the gene therapy is performed against cancer.

18. A commercial package comprising an enhancer as described

in any one of claims 1 through 6, and a package insert describing whether the enhancer can be used or is suggested to be used for gene therapy.

19. The package described in claim 18, wherein the gene therapy is performed against cancer.